+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ablynx  - logo

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, oncology, and respiratory diseases. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

From
From
Autoimmune Collaboration and Licensing Deals 2016-2023 - Product Thumbnail Image

Autoimmune Collaboration and Licensing Deals 2016-2023

  • Report
  • October 2023
  • 450 Pages +
  • Global
From
From
Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 - Product Thumbnail Image

Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030

  • Report
  • January 2020
  • 410 Pages
  • Global
From
Osteoporosis - Pipeline Review, H2 2020 - Product Thumbnail Image

Osteoporosis - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 375 Pages
  • Global
From
From
From
From
Nebulizers - Medical Devices Pipeline Assessment, 2020 - Product Thumbnail Image

Nebulizers - Medical Devices Pipeline Assessment, 2020

  • Report
  • February 2020
  • 119 Pages
  • Global
From
From
From
From
From
Thrombotic Thrombocytopenic Purpura - Pipeline Insight, 2020 - Product Thumbnail Image

Thrombotic Thrombocytopenic Purpura - Pipeline Insight, 2020

  • Clinical Trials
  • February 2020
  • 106 Pages
  • Global
From
Loading Indicator